- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03435718
Efficacia dell'oxfendazolo nel trattamento dell'infezione da Trichuris Trichiura negli adulti
Uno studio comparativo cieco, randomizzato e valutatore dell'efficacia di diverse dosi di oxfendazolo rispetto all'albendazolo a dose singola nel trattamento dell'infezione da Trichuris Trichiura negli adulti
The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an assessor blind, randomized, comparative study in adult patients with proven intestinal infection with Trichuris trichiura to be conducted as a field study. Patients meeting the study entry criteria will receive either 6 mg/kg or 15 mg/kg or 30 mg/kg of oxfendazole as a single oral dose, three single doses of oxfendazole on consecutive days, or albendazole 400mg as a single oral dose. Stool samples will be obtained and examined prior to treatment and at 7, 14 and 21 days after treatment.
Tipo di studio
Fase
- Fase 2
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female outpatient, more than 18 years and less than 65 years of age.
- Written or witnessed oral informed consent has been obtained.
- Trichuris trichiura demonstrated in stool samples obtained during the week before enrolment: The presence of Ascaris lumbricoides, Necator americanus, Ancylostoma duodenalis or other helminths will not be a cause for exclusion.
- Willingness to comply with the requirements of the protocol and particularly to provide 4 stool samples, pretreatment and 7, 14 and 21 days after treatment.
- Female patients of child bearing potential, who are using an established method of birth control (surgically sterile, intra-uterine contraceptive device, oral contraceptives, diaphragm in combination with contraceptive cream or foam, or condom in combination with contraceptive cream or foam) may be included
Exclusion Criteria:
- The patient has demonstrated a previous hypersensitivity reaction to benzimidazole or other related compound.
- Presence of other helminths without Trichuris trichiura. Non-target species may be present and details of response will be recorded.
- The patient has diarrhoeal disease that would interfere with the evaluation of stool samples.
- The patient has received an anthelminthic in the 2 weeks prior to enrolment into the study.
- The patient has received an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit or is scheduled to receive such a drug during the study period.
- The patient has a concomitant infection or any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication.
- The patient has a known history of renal dysfunction or plasma creatinine ≥ 1.5 times upper limit of normal for age or a known history of hepatic dysfunction or liver enzymes ≥ 1.5 times upper limit of normal.
- The patient is a female who is pregnant, lactating or planning a pregnancy during the study, or is not practicing any form of contraception (see inclusion criteria (4.2.5).
- The patient is unwilling or unable to take part in this study.
- The patient has previously been enrolled in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: OXF6
Patients receive a single 6 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
Sperimentale: OXF15
Patients receive a single 15 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
Sperimentale: OXF30
Patients receive a single 30 mg/kg dose of oxfendazole administered orally. |
oral suspension |
|
Sperimentale: OXF15x3
Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days. |
oral suspension |
|
Comparatore attivo: ALB400
Patients receive a single 400 mg/kg dose of albendazole administered orally. |
tablet |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
cure d14
Lasso di tempo: Day 14 of follow up
|
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 14 of follow up
|
|
cure d7
Lasso di tempo: Day 7 of follow up
|
absence of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 7 of follow up
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
improvement d21
Lasso di tempo: Day 21 of follow up
|
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 21 of follow up
|
|
improvement d14
Lasso di tempo: Day 14 of follow up
|
reduction (with respect to the baseline count of that individual) in number of eggs of Trichuris trichiura (determined by the Kato Katz method) in stool samples of treated patients |
Day 14 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d7
Lasso di tempo: Day 7 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 7 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d14
Lasso di tempo: Day 14 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 14 of follow up
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, d21
Lasso di tempo: Day 21 of follow up
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
Day 21 of follow up
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Héctor Hugo Garcia, MD PhD, Oxfendazole Development Group
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni
- Malattie parassitarie
- Infezioni da nematodi
- Elmintiasi
- Infezioni da enoplida
- Infezioni da adenoforesi
- Tricuriasi
- Prodotti chimici organici
- Composti eterociclici
- Benzimidazoli
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Acidi, aciclici
- Acidi carbossilici
- Carbamati
- Albendazolo
- oxfendazole
Altri numeri di identificazione dello studio
- OXF2 v3.21
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data will be uploaded to the clinicaltrials.gov website, and a publication will be prepared
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .